Superluminal Secures $120M Series A Funding to Advance Membrane Receptor Drugs into Clinical Trials

Funding Amount:
Superluminal Medicines has raised $120 million in a Series A funding round.

Investors:
The funding round was backed by Eli Lilly, among other investors.

Purpose:
The funds will be used to advance Superluminal's membrane receptor drugs into clinical trials.

Company Background:
Superluminal Medicines is a Boston-based biotech company that focuses on developing small-molecule drugs.

Previous Funding:
The company had previously secured $33 million in seed funding just over a year ago.